General Information of Drug (ID: DMAH12E)

Drug Name
F-15845 Drug Info
Synonyms
UNII-3VKL9K971D; 3VKL9K971D; F-15845; (-)-F-15845; 2H-1,5-Benzoxathiepin-3-amine, 3,4-dihydro-N-((2S)-3-((2-methoxyphenyl)thio)-2-methylpropyl)-, hydrobromide, (3R)-; 3-(R)-(3-(2-Methoxyphenylthio-2-(S)-methylpropyl)amino)-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate; (-)-(3R)-N-((2S)-3-((2-Methoxyphenyl)sulfanyl)-2-methylpropyl)-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine hydrobromide
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Phase 1 [1]
Cross-matching ID
PubChem CID
72941926
CAS Number
CAS 866760-23-8
TTD Drug ID
DMAH12E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mephenytoin DM5UGDK Epilepsy 8A60-8A68 Approved [3]
Mexiletine DMCTE9R Ventricular tachycardia BC71 Approved [4]
Fosphenytoin DMOX3LB Epilepsy 8A60-8A68 Approved [3]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [4]
LOMERIZINE DME0TC8 Migraine 8A80 Approved [5]
Tetrodotoxin DMWMPRG Bacterial infection 1A00-1C4Z Approved [6]
Dyclonine DMU6OFP Pain MG30-MG3Z Approved [7]
Moricizine DMOMBJW Arrhythmia BC9Z Approved [8]
Ethotoin DMXWOCP Complex partial seizure 8A68.0 Approved [9]
Prilocaine DMI7DZ2 Pain MG30-MG3Z Approved [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A) TTZOVE0 SCN5A_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023448)
2 Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol. 2010 Sep;161(1):79-91.
3 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
4 Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
5 Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
6 Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
7 Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
8 From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
9 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.